NEO Neogenomics Inc

Price (delayed)

$8.32

Market cap

$1.04B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.28

Enterprise value

$1.35B

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose ...

Highlights
The revenue rose by 7% YoY
The equity is up by 27% year-on-year but it is down by 3% since the previous quarter
The quick ratio has contracted by 46% YoY
The gross margin has contracted by 5% YoY and by 2.1% from the previous quarter

Key stats

What are the main financial stats of NEO
Market
Shares outstanding
124.76M
Market cap
$1.04B
Enterprise value
$1.35B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
2.12
EV/EBIT
N/A
EV/EBITDA
46.85
EV/Sales
2.77
Earnings
Revenue
$485.97M
EBIT
-$41.89M
EBITDA
$28.71M
Free cash flow
-$114.5M
Per share
EPS
-$0.28
Free cash flow per share
-$0.93
Book value per share
$8.67
Revenue per share
$3.93
TBVPS
$7.03
Balance sheet
Total assets
$1.83B
Total liabilities
$754.54M
Debt
$613.2M
Equity
$1.08B
Working capital
$569.03M
Liquidity
Debt to equity
0.57
Current ratio
7.93
Quick ratio
7.22
Net debt/EBITDA
10.7
Margins
EBITDA margin
5.9%
Gross margin
37.8%
Net margin
-7.3%
Operating margin
-32%
Efficiency
Return on assets
-1.9%
Return on equity
-3.2%
Return on invested capital
-3.8%
Return on capital employed
-2.4%
Return on sales
-8.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
-2.69%
1 week
5.18%
1 month
-6.41%
1 year
-82.11%
YTD
-75.62%
QTD
-31.52%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$485.97M
Gross profit
$183.72M
Operating income
-$155.68M
Net income
-$35.64M
Gross margin
37.8%
Net margin
-7.3%
The company's operating income fell by 31% QoQ
Neogenomics's operating margin has decreased by 31% from the previous quarter
The revenue rose by 7% YoY
The gross margin has contracted by 5% YoY and by 2.1% from the previous quarter

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
P/E
N/A
P/B
0.96
P/S
2.12
EV/EBIT
N/A
EV/EBITDA
46.85
EV/Sales
2.77
The price to book (P/B) is 80% less than the 5-year quarterly average of 5.0 and 74% less than the last 4 quarters average of 3.8
The equity is up by 27% year-on-year but it is down by 3% since the previous quarter
The price to sales (P/S) is 75% lower than the last 4 quarters average of 8.7 and 68% lower than the 5-year quarterly average of 6.8
The revenue rose by 7% YoY

Efficiency

How efficient is Neogenomics business performance
The return on equity has dropped by 113% year-on-year
The return on assets has dropped by 90% year-on-year
The company's return on sales has shrunk by 79% YoY
NEO's ROIC is down by 15% year-on-year

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 142% greater than the total liabilities
The quick ratio has contracted by 46% YoY
NEO's current ratio is down by 43% YoY
NEO's debt is 43% lower than its equity
The equity is up by 27% year-on-year but it is down by 3% since the previous quarter
The debt to equity has declined by 17% year-on-year but it rose by 3.6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.